Leila Neshatian, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 5
Offices
5 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Neshatian’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A150264 · Current
Licensed to practise in California · since 2017 · expires 2027-03-31 · Shahid Beheshti University of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas Q4648Physician License · since 2015 · expires 2028-08-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$67,464
Medicare paid this office $67,464 for 442 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 131 | $20,952 | $142 |
| New patient visit (60+ min) | 81 | $14,374 | $177 |
| Study of rectum sensitivity and function | 129 | $9,188 | $71 |
| Test for tone and sensation of rectum and anus | 130 | $5,204 | $40 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 127 | $2,201 | $8 |
See all 13 services
| Long return visit (40+ min) | 131 | $20,952 | $142 |
| New patient visit (60+ min) | 81 | $14,374 | $177 |
| Study of rectum sensitivity and function | 129 | $9,188 | $71 |
| Test for tone and sensation of rectum and anus | 130 | $5,204 | $40 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 127 | $2,201 | $8 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,629 | $96 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 67 | $1,109 | $15 |
| Diagnostic exam of anus using an endoscope | 24 | $764 | $32 |
| 3d radiographic procedure with computerized image postprocessing | 22 | $733 | $33 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 23 | $651 | $28 |
| Ultrasound scan of pelvic region through rectum | 17 | $493 | $29 |
| Limited ultrasound scan of pelvis | 23 | $474 | $21 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 16 | $78 | $5 |
Procedures Medicare counted
| Colonoscopy | 23 | More than 50% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 31 | More than 56% of doctors who do this |
Who their Medicare patients are
442 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 9% · Women 72% · Also on Medicaid 25% · Health risk score 1.41. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 59% · Depression 31% · Diabetes 25% · Coronary heart disease 24% · Chronic kidney disease 19% · Cancer 19% · Atrial fibrillation 17% · Heart failure 13% · COPD 12% · Stroke 8% · Dementia 6%.
The office billed $1,104,093, Medicare allowed $88,265 and paid $67,464; for 1,043 services of 32 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 442 | 1,043 | 73 | 1.41 | $1,104,093 | $67,464 |
| 2023 | 515 | 1,087 | 71 | 1.42 | $1,597,015 | $82,387 |
| 2022 | 502 | 1,048 | 72 | 1.47 | $1,711,360 | $96,692 |
| 2021 | 379 | 993 | 70 | 1.33 | $1,571,716 | $89,755 |
| 2020 | 359 | 947 | 70 | 1.53 | $916,603 | $77,489 |
| 2019 | 362 | 950 | 70 | 1.54 | $795,164 | $76,466 |
| 2018 | 272 | 620 | 69 | 1.60 | $530,658 | $58,470 |
| 2017 | 280 | 568 | 70 | 2.57 | $328,388 | $50,621 |
| 2016 | 374 | 883 | 70 | 3.05 | $469,539 | $79,234 |
| 2015 | 96 | 139 | 67 | 2.18 | $58,211 | $15,365 |
| 2014 | 34 | 53 | 70 | 2.06 | $7,505 | $4,835 |
| 2013 | 50 | 75 | 69 | 1.98 | $10,586 | $6,083 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| New patient visit (60+ min) | 141 | $20,684 | $147 |
| Long return visit (40+ min) | 99 | $14,160 | $118 |
| Study of rectum sensitivity and function | 180 | $13,535 | $75 |
| Test for tone and sensation of rectum and anus | 173 | $7,228 | $42 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | $2,692 | $224 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,466 | $154 |
| Return visit (30+ min) | 26 | $2,438 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,385 | $114 |
| Biopsy of large bowel using a flexible endoscope | 13 | $1,877 | $144 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 97 | $1,034 | $8 |
| 3d radiographic procedure with computerized image postprocessing | 29 | $954 | $33 |
| Ultrasound scan of pelvic region through rectum | 29 | $931 | $32 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 26 | $841 | $32 |
| Diagnostic exam of anus using an endoscope | 17 | $632 | $37 |
| Limited ultrasound scan of pelvis | 27 | $572 | $21 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 33 | $147 | $4 |
2022: 17 services
| New patient visit (60+ min) | 131 | $20,227 | $154 |
| Long return visit (40+ min) | 113 | $17,403 | $120 |
| Study of rectum sensitivity and function | 169 | $12,622 | $75 |
| Test for tone and sensation of rectum and anus | 150 | $7,729 | $52 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,340 | $181 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 19 | $4,116 | $217 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,908 | $122 |
| Biopsy of large bowel using a flexible endoscope | 24 | $2,832 | $118 |
| Return visit (30+ min) | 32 | $2,828 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,052 | $93 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,416 | $94 |
| Diagnostic exam of anus using an endoscope | 23 | $893 | $39 |
| Ultrasound scan of pelvic region through rectum | 20 | $589 | $29 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 58 | $519 | $9 |
| 3d radiographic procedure with computerized image postprocessing | 11 | $378 | $34 |
| Limited ultrasound scan of pelvis | 11 | $225 | $20 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 35 | $139 | $4 |
2021: 14 services
| New patient visit (60+ min) | 149 | $24,593 | $165 |
| Long return visit (40+ min) | 111 | $18,979 | $129 |
| Study of rectum sensitivity and function | 157 | $12,592 | $80 |
| Test for tone and sensation of rectum and anus | 154 | $7,923 | $51 |
| Biopsy of large bowel using a flexible endoscope | 24 | $3,358 | $140 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,358 | $214 |
| Return visit (30+ min) | 21 | $1,861 | $89 |
| 3d radiographic procedure with computerized image postprocessing | 35 | $1,226 | $35 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,085 | $83 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 34 | $1,038 | $31 |
| Ultrasound scan of pelvic region through rectum | 34 | $1,017 | $30 |
| Limited ultrasound scan of pelvis | 34 | $733 | $22 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 45 | $417 | $9 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 32 | $137 | $4 |
2020: 19 services
| Long return visit (40+ min) | 83 | $11,277 | $97 |
| New patient visit (60+ min) | 81 | $10,550 | $130 |
| Study of rectum sensitivity and function | 99 | $7,916 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,744 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $4,724 | $96 |
| Test for tone and sensation of rectum and anus | 100 | $4,422 | $44 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | $2,656 | $221 |
| New patient visit (45+ min) | 20 | $2,245 | $112 |
| Return visit (30+ min) | 29 | $2,235 | $70 |
| Biopsy of large bowel using a flexible endoscope | 16 | $2,108 | $132 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,803 | $129 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $1,746 | $87 |
| 3d radiographic procedure with computerized image postprocessing | 37 | $1,298 | $35 |
| Ultrasound scan of pelvic region through rectum | 38 | $1,135 | $30 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 34 | $1,042 | $31 |
| Limited ultrasound scan of pelvis | 36 | $786 | $22 |
| Short return visit (20+ min) | 15 | $739 | $46 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 18 | $168 | $9 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 31 | $146 | $4 |
2019: 18 services
| Study of rectum sensitivity and function | 116 | $9,107 | $79 |
| New patient visit (60+ min) | 59 | $8,547 | $145 |
| Long return visit (40+ min) | 60 | $7,611 | $96 |
| Biopsy of large bowel using a flexible endoscope | 38 | $5,175 | $136 |
| New patient visit (45+ min) | 47 | $5,017 | $107 |
| Test for tone and sensation of rectum and anus | 116 | $5,006 | $43 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,979 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,532 | $93 |
| Return visit (30+ min) | 45 | $3,360 | $65 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 15 | $3,298 | $220 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,951 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,343 | $79 |
| Diagnostic exam of anus using an endoscope | 34 | $1,321 | $38 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,166 | $106 |
| Diagnostic exam of anus with magnification and chemical agent enhancement using an endoscope | 14 | $778 | $56 |
| Ultrasound scan of pelvic region through rectum | 17 | $513 | $30 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 40 | $478 | $9 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 49 | $196 | $4 |
2018: 15 services
| New patient visit (45+ min) | 62 | $6,684 | $108 |
| Return visit (30+ min) | 65 | $6,348 | $65 |
| New patient visit (60+ min) | 38 | $5,231 | $138 |
| Biopsy of large bowel using a flexible endoscope | 30 | $4,162 | $139 |
| Study of rectum sensitivity and function | 51 | $4,058 | $80 |
| Long return visit (40+ min) | 26 | $3,159 | $93 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $3,015 | $232 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,902 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,547 | $182 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,137 | $71 |
| Test for tone and sensation of rectum and anus | 43 | $1,923 | $45 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,589 | $122 |
| Study of esophagus to assess movement | 15 | $966 | $60 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 12 | $110 | $9 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 16 | $76 | $5 |
2017: 12 services
| New patient visit (45+ min) | 75 | $8,080 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $6,004 | $56 |
| Return visit (30+ min) | 51 | $4,737 | $76 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $4,412 | $108 |
| Biopsy of large bowel using a flexible endoscope | 31 | $3,411 | $110 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,156 | $86 |
| Diagnostic exam of large bowel using a flexible endoscope | 17 | $1,865 | $104 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $1,751 | $83 |
| New patient visit (45+ min) | 12 | $1,234 | $103 |
| Short return visit (20+ min) | 17 | $955 | $56 |
| Study of rectum sensitivity and function | 13 | $886 | $68 |
| Test for tone and sensation of rectum and anus | 13 | $489 | $38 |
2016: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 150 | $15,230 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 111 | $12,066 | $108 |
| New patient visit (45+ min) | 66 | $7,872 | $119 |
| Return visit (30+ min) | 68 | $7,315 | $80 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 59 | $5,592 | $90 |
| Biopsy of large bowel using a flexible endoscope | 41 | $5,478 | $134 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 53 | $5,003 | $89 |
| Diagnostic exam of large bowel using a flexible endoscope | 23 | $3,494 | $146 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | $2,527 | $194 |
| Imaging of digestive tract done from the inside of the digestive tract | 15 | $2,458 | $154 |
| Study of rectum sensitivity and function | 28 | $2,000 | $71 |
| Test for tone and sensation of rectum and anus | 28 | $1,138 | $41 |
2015: 5 services
| New patient visit (60+ min) | 18 | $2,932 | $163 |
| Return visit (30+ min) | 23 | $2,087 | $77 |
| New patient visit (45+ min) | 13 | $1,644 | $126 |
| Long return visit (40+ min) | 14 | $1,573 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,164 | $58 |
2014: 1 service
| Return visit (30+ min) | 24 | $2,484 | $78 |
2013: 2 services
| Return visit (30+ min) | 23 | $2,515 | $70 |
| New patient visit (45+ min) | 16 | $1,925 | $120 |
Medicaid work
$3,744 in 2024
Medicaid paid $3,744 for 24 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| ANORECTAL MANOMETRY | 24 | $3,744 |
| 2024 | 24 | 1 | 12 | $3,744 |
| 2023 | 81 | 2 | 15 | $5,551 |
| 2022 | 12 | 1 | 12 | $2,170 |
| 2021 | 14 | 1 | 14 | $642 |
| 2018 | 28 | 2 | 13 | $489 |
See the largest Medicaid services in earlier years
2023
| ANORECTAL MANOMETRY | 66 | $5,175 |
| Breath hydrogen test | 15 | $376 |
2022
| ANORECTAL MANOMETRY | 12 | $2,170 |
2021
| ANORECTAL MANOMETRY | 14 | $642 |
2018
| TISSUE EXAM BY PATHOLOGIST | 12 | $398 |
| Injection, midazolam hydrochloride, per 1 mg | 16 | $91 |
Drugs they prescribed that Part D paid
$176,417
Pharmacies billed $176,417 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 278) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
114 generic and 164 brand-name prescriptions · $176,417 in drug cost · 18 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 54 | $57,875 | $1,072 |
| Ibsrela | 17 | $35,078 | $2,063 |
| Motegrity | 36 | $26,134 | $726 |
| Trulance | 19 | $11,528 | $607 |
| Colesevelam | 13 | $977 | $75 |
See all 7 drugs
| Linzess | 54 | $57,875 | $1,072 |
| Ibsrela | 17 | $35,078 | $2,063 |
| Motegrity | 36 | $26,134 | $726 |
| Trulance | 19 | $11,528 | $607 |
| Colesevelam | 13 | $977 | $75 |
| Omeprazole | 21 | $532 | $25 |
| Peg 3350-Electrolyte | 15 | $274 | $18 |
Year by year
| 2024 | 278 | 113 | 0% (0) | 59% | $176,417 |
| 2023 | 404 | 164 | 0% (0) | 52% | $181,950 |
| 2022 | 513 | 189 | 0% (0) | 56% | $193,079 |
| 2021 | 496 | 165 | 0% (0) | 54% | $179,286 |
| 2020 | 417 | 132 | 0% (0) | 51% | $167,661 |
| 2019 | 300 | 120 | 0% (0) | 49% | $104,307 |
| 2018 | 192 | 74 | 0% (0) | 40% | $46,866 |
| 2017 | 260 | 115 | None | 40% | $56,818 |
| 2016 | 207 | 90 | 0% (0) | 42% | $39,435 |
| 2015 | 84 | 34 | None | 26% | $25,358 |
| 2014 | 68 | 26 | None | None | $10,172 |
| 2013 | 64 | 20 | 0% (0) | 41% | $15,005 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Linzess | 67 | $60,233 | $899 |
| Motegrity | 63 | $42,902 | $681 |
| Ibsrela | 12 | $19,925 | $1,660 |
| Trulance | 20 | $18,172 | $909 |
| Movantik | 15 | $8,837 | $589 |
| Peg 3350-Electrolyte | 34 | $860 | $25 |
| Omeprazole | 40 | $778 | $19 |
| Gavilyte-G | 12 | $189 | $16 |
| Amitriptyline | 15 | $182 | $12 |
| Constulose | 12 | $25 | $2 |
2022: 11 drugs
| Linzess | 96 | $90,611 | $944 |
| Motegrity | 90 | $46,666 | $519 |
| Trulance | 19 | $10,991 | $578 |
| Movantik | 25 | $10,356 | $414 |
| Lubiprostone | 11 | $3,104 | $282 |
| Peg 3350-Electrolyte | 47 | $1,030 | $22 |
| Ondansetron Odt | 12 | $647 | $54 |
| Omeprazole | 20 | $591 | $30 |
| Gabapentin | 24 | $480 | $20 |
| Mirtazapine | 12 | $124 | $10 |
| Metronidazole | 14 | $90 | $6 |
2021: 13 drugs
| Linzess | 91 | $74,927 | $823 |
| Xifaxan | 18 | $35,938 | $1,997 |
| Motegrity | 58 | $30,951 | $534 |
| Movantik | 22 | $8,304 | $377 |
| Lubiprostone | 16 | $4,694 | $293 |
| Suprep | 14 | $1,517 | $108 |
| Omeprazole | 27 | $549 | $20 |
| Pantoprazole | 18 | $451 | $25 |
| Peg 3350-Electrolyte | 27 | $437 | $16 |
| Famotidine | 11 | $286 | $26 |
| Dicyclomine | 16 | $228 | $14 |
| Metronidazole | 14 | $94 | $7 |
| Diltiazem | 14 | $27 | $2 |
2020: 11 drugs
| Linzess | 67 | $51,528 | $769 |
| Motegrity | 52 | $27,616 | $531 |
| Xifaxan | 12 | $23,497 | $1,958 |
| Amitiza | 23 | $10,683 | $464 |
| Colesevelam | 13 | $5,404 | $416 |
| Pyridostigmine | 15 | $2,747 | $183 |
| Omeprazole | 30 | $914 | $30 |
| Gavilyte-G | 19 | $261 | $14 |
| Dicyclomine | 14 | $237 | $17 |
| Pantoprazole | 13 | $206 | $16 |
| Metronidazole | 14 | $108 | $8 |
2019: 7 drugs
| Linzess | 35 | $28,185 | $805 |
| Motegrity | 45 | $22,260 | $495 |
| Amitiza | 16 | $7,282 | $455 |
| Omeprazole | 35 | $596 | $17 |
| Gavilyte-G | 24 | $340 | $14 |
| Dicyclomine | 11 | $213 | $19 |
| Metronidazole | 14 | $80 | $6 |
2018: 4 drugs
| Linzess | 37 | $23,677 | $640 |
| Omeprazole | 21 | $390 | $19 |
| Dicyclomine | 24 | $335 | $14 |
| Peg 3350-Electrolyte | 11 | $203 | $18 |
2017: 8 drugs
| Linzess | 29 | $18,540 | $639 |
| Esomeprazole Magnesium | 12 | $3,664 | $305 |
| Moviprep | 26 | $2,406 | $93 |
| Suprep | 15 | $1,382 | $92 |
| Omeprazole | 40 | $926 | $23 |
| Pantoprazole | 14 | $193 | $14 |
| Dicyclomine | 11 | $148 | $13 |
| Metronidazole | 15 | $101 | $7 |
2016: 7 drugs
| Amitiza | 21 | $7,525 | $358 |
| Linzess | 11 | $4,923 | $448 |
| Esomeprazole Magnesium | 13 | $4,062 | $312 |
| Moviprep | 34 | $3,019 | $89 |
| Omeprazole | 31 | $629 | $20 |
| Polyethylene Glycol 3350 | 11 | $195 | $18 |
| Pantoprazole | 11 | $145 | $13 |
2014: 1 drug
| Omeprazole | 24 | $706 | $29 |
2013: 1 drug
| Omeprazole | 11 | $262 | $24 |
Money from drug and device companies
$2,904 in 2025
| 2025 | 5 | 9 | $2,400 | $2,904 |
| 2024 | 3 | 3 | None | $304 |
| 2023 | 3 | 5 | None | $282 |
| 2022 | 3 | 6 | $5,700 | $24,507 |
| 2021 | 3 | 3 | $1,125 | $1,207 |
| 2019 | 3 | 3 | None | $267 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $2,642 | 5 payments
|
| Ardelyx | Ibsrela | $139 | 1 payment
|
| Medtronic | Interstim | $57 | 1 payment
|
| Teleflex | Solesta | $36 | 1 payment
|
| Mauna Kea Technologies | None | $29 | 1 payment
|
See all 9 published payments
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-01 | Xifaxan | $45 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-16 | Xifaxan | $82 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-02 | Xifaxan | $68 |
| Mauna Kea Technologies | Meals · 2025-07-21 | None | $29 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-30 | Xifaxan | $48 |
| Medtronic | Meals · 2025-06-27 | Interstim | $57 |
| Salix Pharmaceuticals a division of Bausch Health US | Consulting · 2025-06-09 | None | $2,400 |
| Ardelyx | Meals · 2025-06-05 | Ibsrela | $139 |
| Teleflex | Meals · 2025-01-13 | Solesta | $36 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $304
| Vibrant Gastro | Vibrant Starter Kit | $142 | 1 payment
|
| Ardelyx | Ibsrela | $135 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $27 | 1 payment
|
2023: $282
| Cook Biotech | None | $126 | 1 payment
|
| Ardelyx | Ibsrela | $81 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $75 | 2 payments
|
2022: $24,507
| Ironwood Pharmaceuticals | None | $18,550 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $4,457 | 4 payments
|
| Ardelyx | Ibsrela | $1,500 | 1 payment
|
2021: $1,207
| GI Supply | None | $1,125 | 1 payment
|
| Medtronic | Gi Genius | $47 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $35 | 1 payment
|
2019: $267
| Alnylam Pharmaceuticals | Onpattro | $113 | 1 payment
|
| Medtronic USA | Interstim Icon | $82 | 1 payment
|
| Allergan | Linzess | $72 | 1 payment
|
Professional record
- NPI
- 1710275722
- Licence
- CA A150264, MN 106246, NY 003872, TX Q4648California A150264: Current · expires 2027-03-31Texas Q4648: Active
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- TX 348455201, TX 348455202, TX 348455203
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-07-12
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.